Could CAR-T therapy change the treatment landscape for glioblastoma? – Video Journal of Oncology
Video Journal of Oncology (VJOncology) shared a post on LinkedIn:
“March is Brain Tumor Awareness Month in the UK.
Could CAR-T therapy change the treatment landscape for glioblastoma (GBM)?
At the EHA-EBMT 7th European CAR T-cell Meeting, Dr. Denis Migliorini (University of Geneva) shared insights into two innovative clinical cell products targeting overexpressed peptides in GBM.
Key highlights include:
- A CART therapy using RNA-based technology to target PTPRZ1, a phosphatase receptor
- A novel approach targeting a secreted extracellular matrix molecule
- The potential to inhibit tumor invasiveness by disrupting key molecular interactions
As the field of cell therapy continues to evolve, could these advancements offer new hope for highly aggressive brain tumors?
Alfredo Addeo, Head of the Oncology Department at University Hospitals of Geneva, shared this post adding:
“Dr. Denis Migliorini, is a brilliant medical oncologist who actively contributes to the influence of the University Hospitals of Geneva. He is currently in charge of the neuro-oncology unit and also one of the assistant physicians in my medical oncology department, which I have the honor to lead.
Thanks to his innovative research work, particularly in the field of CAR-T therapies and brain cancers, we sincerely hope that he will be able to play a major role in improving the lives of patients in Geneva affected by these dreadful and complex diseases.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023